BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22622260)

  • 21. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].
    Wang X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Sep; 21(9):686-691. PubMed ID: 30201068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
    Dong X; Fernandez-Salas E; Li E; Wang S
    Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
    Heuckmann JM; Rauh D; Thomas RK
    J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
    [No Abstract]   [Full Text] [Related]  

  • 27. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA; Velez M; Raez LE; Santos ES
    Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy for NSCLC: ALK inhibition.
    Pearson R; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM; Bepler G
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
    Berghoff AS; Birner P; Streubel B; Kenner L; Preusser M
    APMIS; 2014 Sep; 122(9):867-72. PubMed ID: 24750504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.
    Lozano MD; Labiano T; Zudaire I; Subtil JC; Gúrpide A; Echeveste JI; Zulueta JJ; Martín-Algarra S; Pérez-Gracia JL
    Int J Surg Pathol; 2015 Apr; 23(2):111-5. PubMed ID: 24942894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
    Sauter JL; Butnor KJ
    Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.
    Boland JM; Jang JS; Li J; Lee AM; Wampfler JA; Erickson-Johnson MR; Soares I; Yang P; Jen J; Oliveira AM; Yi ES
    J Thorac Oncol; 2013 May; 8(5):574-81. PubMed ID: 23449277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M; Wynes MW; Hirsch FR
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas.
    Liu C; Pepper K; Hendrickson H; Cagle PT; Portier BP
    Arch Pathol Lab Med; 2016 Jul; 140(7):690-3. PubMed ID: 26599807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis.
    Wang Z; Yang H; Luo S; Liu B; Zhang N; Li L; Zhou S; Shen R; Xie X
    Lung Cancer; 2017 Oct; 112():1-9. PubMed ID: 29191580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.